All In Biotech

Drug Trial Radar · NCT06279533

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules in Chinese Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Feb 27, 2024

Primary completion

Dec 17, 2024

Study completion Dec 17, 2024

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is divided into two parts: the safety, tolerability, pharmacokinetic profiles of LV232 capsules after multiple ascending doses (hereinafter referred to as "PK characteristics of multiple ascending doses study ") and food effect study (hereinafter referred to as "FE study"). A total of 48 subjects are planned to be enrolled. The two parts of the study can be carried out simultaneously, and there is no order requirement.

Conditions

  • Healthy Subjects

Interventions

  • LV232/PlaceboDrug

    Drug: LV232 15mg Group: 6 subjects will receive LV232 15mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally. Drug: LV232 40mg Group: 6 subjects will receive LV232 40mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally. Drug: LV232 60mg Group: 6 subjects will receive LV232 60mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.

  • LV232Drug

    Drug: LV232 20mg Group: 12 subjects will receive LV232 20mg, orally Drug: LV232 60mg Group: 12 subjects will receive LV232 60mg, orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TmaxTime frame: Calculated using concentration data collected from predose to 72 hours postdose
  2. CmaxTime frame: Calculated using concentration data collected from predose to 72 hours postdose
  3. T1/2Time frame: Calculated using concentration data collected from predose to 72 hours postdose
  4. AUC0-tTime frame: Calculated using concentration data collected from predose to 72 hours postdose
  5. AUC0-24hTime frame: Calculated using concentration data collected from predose to 24 hours postdose
  6. AUC0-∞Time frame: Calculated using concentration data collected from predose to 72 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.